IP Library › Granted Patent US 8,765,956
Granted Patent B2
US 8,765,956 · App. 13/912,483 · Granted Jul 1, 2014

Nitrogen-containing heteroaryl compounds and methods of use thereof

Inventors: Michael P. Arend (Foster City, CA); Lee A. Flippin (Woodside, CA); Volkmar Guenzler-Pukall (San Leandro, CA); Wen-Bin Ho (Los Altos, CA); Eric D. Turtle (Belmont, CA); Xiaohui Du (Foster City, CA)
Assignee: Fibrogen, Inc.
C07D217/26C07D217/24
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,765,956
App. No.
13/912,483
Granted
Jul 1, 2014
Kind
B2
Abstract

The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.

Claims (37)

1. A compound of formula:

or a pharmaceutically acceptable salt thereof.

2. A compound of formula:

or a pharmaceutically acceptable salt thereof.

3. A compound of formula:

or a pharmaceutically acceptable salt thereof.

4. A compound of formula:

or a pharmaceutically acceptable salt thereof.

5. A compound of formula:

or a pharmaceutically acceptable salt thereof.

6. A compound of formula:

or a pharmaceutically acceptable salt thereof.

7. A compound of formula:

or a pharmaceutically acceptable salt thereof.

8. A compound of formula:

or a pharmaceutically acceptable salt thereof.

9. A compound of formula:

or a pharmaceutically acceptable salt thereof.

10. A compound of formula:

or a pharmaceutically acceptable salt thereof.

11. A compound of formula:

or a pharmaceutically acceptable salt thereof.

12. A compound of formula:

or a pharmaceutically acceptable salt thereof.

13. A compound of formula:

or a pharmaceutically acceptable salt thereof.

14. A compound of formula:

or a pharmaceutically acceptable salt thereof.

15. A compound of formula:

or a pharmaceutically acceptable salt thereof.

16. A compound of formula:

or a pharmaceutically acceptable salt thereof.

17. A compound of formula:

or a pharmaceutically acceptable salt thereof.

18. A compound of formula:

or a pharmaceutically acceptable salt thereof.

19. A compound of formula:

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Sep 3, 2025
From: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT
To: FIBROGEN, INC.
Reel/Frame 072785/0760 →
SECURITY INTEREST Recorded May 1, 2023
From: FIBROGEN, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 063504/0221 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 16, 2013
From: AREND, MICHAEL P.; FLIPPIN, LEE A.; GUENZLER-PUKALL, VOLKMAR; HO, WEN-BIN; TURTLE, ERIC D.; DU, XIAOHUI
To: FIBROGEN, INC.
Reel/Frame 031215/0760 →
Continuity (9)
Continuation 13599161 · Aug 30, 2012
Continuation 13186351 · Jul 19, 2011
Continuation 12015275 · Jan 16, 2008
Division 10861082 · Jun 4, 2004
Provisional Application 60476633 · Jun 6, 2003
Provisional Application 60476519 · Jun 6, 2003
Provisional Application 60476811 · Jun 6, 2003
Provisional Application 60476420 · Jun 6, 2003
Related Publication 20130310565A1 · Nov 21, 2013